AMRXAmneal Pharmaceuticals, Inc.

$4B

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$659M+18.2% YoY

Gross Profit

$238M36.1% margin

Operating Income

-$11M-1.6% margin

Net Income

-$92M-13.9% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+6.8%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$24M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$3.5B

Stockholders' Equity

-$64M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$659M	$558M	+18.2%
Gross Profit	$238M	$178M	+33.6%
Operating Income	-$11M	$34M	-131.2%
Net Income	-$92M	-$7M	-1219.9%

Revenue Segments

Generics Segment

$391M79%

Amneal Specialty Pharma Segment

$105M21%

AMRX Q1 2024 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena